Recommendations from treatment guidelines for Schizophrenia regarding monitoring of side effects of antipsychotics: Brief review

Psychiatria Danubina

Volumn 21, Issue 1, 2009, Pages 95-98

  Kozumplik, Oliver ^a   Uzun, Suzana ^a  

^a Referentni centar za Alzheimerovu bolest i psihijatriju sta rijeivo t ne dobi   (Croatia)

Author keywords

Antipsychotic; Schizophrenia; Side effects; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT;

CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; KETOACIDOSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NEUROLOGIC DISEASE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; RELAPSE; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DRUG MONITORING; HUMANS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 63649135851     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. American Psychiatric Association: Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Am J Psychiatry 2004; 161: 1-114.
2. Canadian Psychiatric Association Working Group Members: Clinical Practice Guidelines Treatment of Schizophrenia. Can J Psychiatry 2005; 50.
3. Cohn TA & Sernyak AJ: Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006: 51:492-501.
4. Jakovljević M: Myths and facts in contemporary psychopharmacotherapy: evidence-based vs. evidence-biased treatment algorithms practice. Psychiatr Danub 2007; 19:342-49.
5. Kane JM & Lieberman JA: Adverse Effects of Psychotropic Drugs. New York: Guilford, 1992.
6. Kane JM, Leucht S, Carpenter D, Docherty JP; Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64:5-19.
7. National Institute for Clinical Excellence: Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43. London: NICE, 2002.
8. Newcomer JW: Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19:1-93.
9. Remington G: Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr Opin Psychiatry 2007; 20:131-7.
10. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders: Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Australian and New Zealand Journal of Psychiatry 2005; 39:1-30.
11. Ruetsch O, Viala A, Bardou H, Martin P & Vacheron MV: Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management. Encephale 2005; 31:507-16.
12. Sernyak MJ: Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007; 68:14-8.
13. Tarsy D & Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord. 2006; 21:589-98.
14. van Winkel R, De Hert M, Van Eyck D, Hanssens L, Wampers M, Scheen A & Peuskens J: Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry 2006; 67:1493-500.